BusinessNeothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous FatBy Nasdaq OMXDec 23, 2016, 1:00 PM UTC
BusinessNeothetics Provides Business Update and Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 10, 2016, 1:00 PM UTC
BusinessNeothetics Announces Leadership Change and Preliminary Update on LIPO-202By Nasdaq OMXFeb 18, 2016, 9:00 PM UTC
